Advanced Breast Cancer

Sunitinib+Docetaxel Not Recommended for First-Line Treatment of HER2/neu Advanced Breast Cancer

The combination of sunitinib plus docetaxel improved the objective response rate (ORR) but did not prolong progression-free survival (PFS) or overall survival (OS) vs. docetaxel alone for the first-line treatment of HER2/neu-negative advanced breast cancer, a Phase 3 randomized study concluded in the Journal of Clinical Oncology online February 13.

Hormone Receptor Levels Predict Trastuzumab Effect

Patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer whose tumors also express hormone receptors may be less responsive to the addition of trastuzumab to chemotherapy, suggesting that hormone-receptor expression has a predictive role in determining response to therapy.

Next post in Breast Cancer